Cellectis S.A.
corporate_fare Company Profile
Cellectis S.A. (NASDAQ:CLLS) is a publicly traded company in the Life Sciences sector. Wiseek monitors CLLS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Cellectis Reports Strong Phase 1 Data for Lasme-cel (100% ORR) and Promising Eti-cel Results at EHA
- Cellectis's CAR-T Therapy Lasme-cel Receives FDA RMAT Designation for r/r B-ALL
- FDA Grants RMAT Designation to Cellectis's Lead CAR-T Therapy lasme-cel for r/r B-ALL
- Cellectis Seeks Shareholder Approval for Massive Dilutive Capital Raises and ATM Program
- Cellectis to Present Promising Clinical Data for Lasme-cel and Eti-cel at EHA 2026 Congress
Financial Snapshot
Insider Transactions
CLLS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.